Shares of MaxCyte, Inc. (LON:MXCT – Get Free Report) reached a new 52-week low during trading on Friday . The stock traded as low as GBX 177 ($2.35) and last traded at GBX 180 ($2.39), with a volume of 59004 shares traded. The stock had previously closed at GBX 201 ($2.67).
MaxCyte Stock Performance
The stock’s 50-day moving average is GBX 216.58 and its 200 day moving average is GBX 283.22. The stock has a market cap of £237.61 million, a price-to-earnings ratio of -6.60 and a beta of 1.13. The company has a debt-to-equity ratio of 8.59, a current ratio of 9.81 and a quick ratio of 14.38.
MaxCyte Company Profile
MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients.
Featured Articles
- Five stocks we like better than MaxCyte
- What is the NASDAQ Stock Exchange?
- Constellation Powers Up With Reinforced AI Data Center Strategy
- Top Biotech Stocks: Exploring Innovation Opportunities
- Top Analyst-Rated Healthcare Stocks to Watch Now
- Pros And Cons Of Monthly Dividend Stocks
- GlobalFoundries Stock Hits Bottom: Is a Rebound Coming?
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
